Dr. Michelle Dipp is the founding Chief Executive Officer of OvaScience and serves on the company’s Board of Directors. Michelle is also a Founder and Partner of Longwood Fund, which founds and invests in healthcare companies such as Alnara (acquired by Eli Lilly in 2010) and Verastem (NASDAQ:VSTM). Previously, Michelle was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior to that, she was Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), where she led the successful acquisition of Sirtris by GSK in June 2008 for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Michelle serves on the Beth Israel Deaconess Medical Center Board of Trustees and the Board of Directors of the City on a Hill Charter School in Roxbury, Mass.
Michelle holds an M.D. and a Ph.D. from the University of Oxford.